kallikrein

(redirected from Plasma kallikrein)
Also found in: Medical.

kallikrein

(ˌkælɪˈkriːɪn; kəˈlɪkriːɪn)
n
(Biochemistry) a type of protease that liberates kinins from kininogens
Translations

kal·li·kre·in

n. calicreína, enzima potente de acción vasodilatadora.
References in periodicals archive ?
A publicly traded, Massachusetts-based biotechnology firm, Dyax is mainly focused on the development of plasma kallikrein (pKal) inhibitors for the treatment of HAE, a debilitating and sometimes life-threatening rare genetic disease.
KalVista will use the funds to advance its proprietary portfolio of plasma kallikrein inhibitors for treating diabetic macular edema (DME) and hereditary angioedema (HAE).
DX-2930 is a Potent, Highly Specific, and Potentially Long-Acting Antibody Inhibitor of Plasma Kallikrein
Studies in the lab of Joslin Investigator Edward Feener have pinpointed a new mechanism involving a protein called plasma kallikrein that interferes with the normal clotting process in the brain following blood vessel injury with diabetes.
ITIH4 is highly sensitive to plasma kallikrein and has been proposed to be a potential precursor for plasma kallikrein-induced bioactive peptides (1, 2).
An increase in capillary permeability was not seen following direct intradermal injection of either the venom enzyme or plasma kallikrein.
Food and Drug Administration (FDA) has granted Fast Track designation for its BCX4161, a novel, orally administered, selective inhibitor of plasma kallikrein in advanced clinical development for the treatment of hereditary angioedema.
These peptides might be generated by action of proteases such as thrombin and plasma kallikrein (Table 1).
In addition, this project will provide KalVista with access to new ophthalmology projects and dovetails nicely with our internal programmes focused on intravitreal and oral plasma kallikrein inhibitors for DME.
Among the known kallikrein enzymes, only plasma kallikrein (encoded by a single gene localized on human chromosome 4835; official symbol KLKB1) and pancreatic/renal kallikrein (hK1) have significant kininogenase activity.
In addition, BioCryst has several early-stage programs: BCX4161 and a next generation oral inhibitor of plasma kallikrein for hereditary angioedema and BCX4430, a broad spectrum antiviral for hemorrhagic fevers.